Although the advent of HER2-targeted therapy has improved prognosis for HER2+ breast cancer,68 a large percentage of HER2+ tumors will nonetheless fail to achieve optimal preoperative response to a combination of chemotherapy and anti-HER2 therapy.1,2 In this study, the findings suggest that DCE-MRI peritumoral radiomics may enable noninvasive intrinsic subtyping of HER2+ breast cancer into response-associated subgroups. This evidence concerns the gene ERBB2 and breast cancer.